PLC would like to recognize Neurelis’ announcement regarding initiation of their study of VALTOCO® in the pediatric population

20 September 2021 – PLC would like to recognize Neurelis’ announcement regarding initiation of their study of VALTOCO^® in the pediatric population. PLC has supported the clinical development and regulatory pathway of VALTOCO with Neurelis from inception and is providing clinical oversight of this trial in addition to continued Regulatory filings in the US.

NEURELIS INITIATES STUDY OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN CHILDREN WITH SEIZURE CLUSTERS AGED TWO TO FIVE

VALTOCO is currently approved by the FDA as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters or acute repetitive seizures) that are distinct from an individual’s usual seizure pattern in patients with epilepsy 6 years of age and older

https://neurelis.com/neurelis-initiates-study-valtocor-diazepam-nasal-spray-children-seizure-clusters-aged-two-five

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Related Posts

Congratulations to Neurelis on their accepted presentations at the upcoming Annual Meeting of the American Academy of Neurolgy

PLC recognizes Neurelis’ recent announcement concerning first dosing of their first-in-human study to treat patients with cerebral cavernous malformation (CCM) with NRL-1049, a Rho kinase (ROCK) inhibitor

Congratulations to ARS Pharmaceuticals on their five accepted poster presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting.